{
    "clinical_study": {
        "@rank": "107601", 
        "arm_group": [
            {
                "arm_group_label": "NI-071", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Infliximab", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate similarity between NI-071 and infliximab(the\n      comparator) in terms of efficacy in patients with Rheumatoid Arthritis not adequately\n      responding to Methotrexate."
        }, 
        "brief_title": "A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with a diagnosis of RA as defined by the American College Rheumatology (ACR)\n             and European League Against Rheumatism (EULAR) criteria (ACR/EULAR 2010)\n\n          2. Patients who received MTX treatment (6- 16mg/week) for 2 weeks for at least 12 weeks\n             prior to the screening visit\n\n        Exclusion Criteria:\n\n          1. Patients with a following past History or concomitant diseases\n\n               -  Other Connective tissue disorders  which may interfere the efficacy assessment\n\n               -  Chronic or recurrent infectious disease\n\n               -  Demyelinating disease\n\n               -  Congestive heart failure\n\n               -  lymphoproliferative disorder or myelodysplastic syndrome\n\n               -  Malignancy\n\n               -  Interstitial lung disease\n\n          2. Patients with active or latent tuberculosis or history of tuberculosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927263", 
            "org_study_id": "NI071F1(EFC13464)"
        }, 
        "intervention": [
            {
                "arm_group_label": "NI-071", 
                "description": "100mg/vial", 
                "intervention_name": "NI-071", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Infliximab", 
                "description": "100mg/vial", 
                "intervention_name": "Infliximab", 
                "intervention_type": "Biological", 
                "other_name": "Remicade"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "contact": {
                "email": "hiroshi-bando@nichiiko.co.jp", 
                "last_name": "For site information, send an email with site number to"
            }, 
            "facility": {
                "address": {
                    "city": "Sendai-Shi", 
                    "country": "Japan"
                }, 
                "name": "NichiIko Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Clinical Study of NI-071 in Patients With Rheumatoid Arthritis \u2015A Double-blind, Active Drug-controlled Study and Long-term Study\u2015", 
        "overall_contact": {
            "email": "hiroshi-bando@nichiiko.co.jp", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficacy : Changes in DAS28-ESR", 
            "safety_issue": "No", 
            "time_frame": "week 0 to week 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927263"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy : Changes in DAS28", 
                "safety_issue": "No", 
                "time_frame": "week 0 to week 54"
            }, 
            {
                "measure": "Efficacy : Changes in ACR20, 50, 70", 
                "safety_issue": "No", 
                "time_frame": "week 0 to week 54"
            }, 
            {
                "measure": "Efficacy : Changes in ACR core-set", 
                "safety_issue": "No", 
                "time_frame": "week 0 to week 54"
            }, 
            {
                "measure": "Safety : Long term safety (Adverse Events, Immunogenicity, etc.)", 
                "safety_issue": "Yes", 
                "time_frame": "to 54 weeks"
            }
        ], 
        "source": "Nichi-Iko Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nichi-Iko Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}